Steady-state methadone in rats does not change mRNA levels of corticotropin-releasing factor, its pituitary receptor or proopiomelanocortin

European Journal of Pharmacology
Y ZhouM J Kreek

Abstract

Male Fischer rats received either methadone (a long-acting opioid agonist, 10 mg/kg/day) or saline (24 microliters/day) subcutaneously by osmotic minipumps for 7 days. Chronic steady-state methadone administration did not alter (a) corticotropin-releasing factor (CRF) mRNA in the hypothalamus, (b) proopiomelanocortin (POMC) and CRF type 1 receptor (CRF-R1) mRNAs in the anterior lobe and neurointermediate/posterior lobe of the pituitary, or (c) circulating levels of corticosterone. No change was found in levels of either POMC mRNA in the hypothalamus and amygdala, or CRF mRNA in the frontal cortex, olfactory bulb and amygdala. These results demonstrate that neither the activity of the hypothalamic-pituitary-adrenal axis, nor the beta-endorphin and CRF systems in the brain, are altered by steady-state occupancy of opioid receptors with the long-acting opioid agonist methadone.

References

Feb 5, 1973·JAMA : the Journal of the American Medical Association·M J Kreek
Sep 13, 1994·Proceedings of the National Academy of Sciences of the United States of America·E PotterW Vale

❮ Previous
Next ❯

Citations

Jan 20, 2012·Psychopharmacology·Erin CumminsFrancesco Leri
Jan 3, 2001·European Journal of Pharmacology·D LichtermannM L Rao
Aug 26, 1998·Drug and Alcohol Dependence·M J Kreek, G F Koob
Dec 3, 2008·Behavioral Neuroscience·N DevidzeM J Kreek
Sep 5, 2002·Nature Reviews. Drug Discovery·Mary Jeanne KreekEduardo Butelman
Oct 21, 2005·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Francesco LeriMary Jeanne Kreek
Oct 2, 2012·The Journal of Clinical Investigation·Mary Jeanne KreekEduardo R Butelman
Oct 12, 2010·Medical Hypotheses·Albert Stuart Reece
May 1, 2009·Expert Opinion on Drug Discovery·Erin Cummins, Francesco Leri
Mar 25, 2004·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Francesco LeriJane Stewart
Jan 5, 2000·Journal of Neurochemistry·P A IredaleR S Duman
Sep 5, 2003·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Francesco LeriJane Stewart
Aug 14, 2003·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Hani HoushyarMary F Dallman
Apr 18, 2003·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·James H SchlugerMary Jeanne Kreek
Sep 7, 2004·The Journal of Pharmacology and Experimental Therapeutics·Jan K MelicharDavid J Nutt
Oct 6, 1997·Science·G F Koob, M Le Moal
Dec 7, 2017·Journal of Psychopharmacology·Stephen DanielsFrancesco Leri

❮ Previous
Next ❯

Related Concepts

Related Feeds

Amygdala and Midbrain Dopamine

The midbrain dopamine system is widely studied for its involvement in emotional and motivational behavior. Some of these neurons receive information from the amygdala and project throughout the cortex. When the circuit and transmission of dopamine is disrupted symptoms may present. Here is the latest research on the amygdala and midbrain dopamine.

Amygdala: Sensory Processes

Amygdalae, nuclei clusters located in the temporal lobe of the brain, play a role in memory, emotional responses, and decision-making. Here is the latest research on sensory processes in the amygdala.